| Variable |
Summarya (N=12) |
| Completed 3 month treatment of 3 drugs in study |
12 (100%) |
| Completed 6 month follow-up |
11 (92%) |
| Age at consent date |
69 (62, 76) |
| Sex - Female |
9 (75%) |
| Race - Caucasian |
12 (100%) |
| Change in disease severity prior to enrollment |
|
| Stable |
6 (50%) |
| Slight deterioration |
1 (8%) |
| Worse |
5 (42%) |
| Never smokedb |
7 (58%) |
| History of hemoptysis in last 6 months |
2 (17%) |
| Hemoptysis while on treatment |
0 (0%) |
| BMI (kg/m2) |
23.2 (18.6, 23.9) |
| FEV1 (L) |
1.8 (1.3, 2.0) |
| pp FEV1 (%) |
64 (47, 70) |
| FEV1/FVC (%) |
63 (59, 74) |
| DLCO |
14.0 (11.7, 17.2) |
| pp DLCO (%) |
66 (60, 74) |
| aThe sample median (25th, 75th percentiles) is given for numerical variables, n (%) for categorical variables. bNo patients were current smokers. |
|
